» Articles » PMID: 35936740

Commencing Colorectal Cancer Screening at Age 45 Years in U.S. Racial Groups

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Aug 8
PMID 35936740
Authors
Affiliations
Soon will be listed here.
Abstract

Screening for colorectal cancer (CRC) is cost-effective for reducing its mortality among the average-risk population. In the US, CRC incidence and mortality differ among racial/ethnic groups, with non-Hispanic Blacks (NHB) and American Indian/Alaska Natives showing highest incidence and mortality and earlier presentation. Since 2005, some professional societies have recommended CRC screening for NHB to commence at 45 years or earlier; this was not implemented due to lack of recommendation from key groups that influence insurance payment coverage. In 2017 the highly influential U.S. Multi-Society Task Force for Colorectal Cancer recommended screening to commence at 45 years for NHB; this recommendation was supplanted by data showing an increase in early-onset CRCs in non-Hispanic Whites approaching the under-50-year rates observed for NHB. Subsequently the American Cancer Society and the USPSTF recommended that the entire average-risk population move to commence CRC screening at 45 years. Implementing screening in 45-49-year-olds has its challenges as younger groups compared with older groups participate less in preventive care. The US had made extensive progress pre-COVID-19 in closing the disparity gap for CRC screening in NHB above age 50 years; implementing screening at younger ages will take ingenuity, foresight, and creative strategy to reach a broader-aged population while preventing widening the screening disparity gap. Approaches such as navigation for non-invasive and minimally invasive CRC screening tests, removal of financial barriers such as co-pays, and complete follow up to abnormal non-invasive screening tests will need to become the norm for broad implementation and success across all racial/ethnic groups.

Citing Articles

Trends and Symptoms Among Increasing Proportion of African Americans with Early-Onset Colorectal Cancer over a 60-Year Period.

Brim H, Reddy C, Chirumamilla L, Oskrochi G, Deverapalli M, Rashid R Dig Dis Sci. 2024; 70(1):168-176.

PMID: 39586927 DOI: 10.1007/s10620-024-08739-5.


THE JEREMIAH METZGER LECTURE: ENVIRONMENTAL INFLUENCES ON COLORECTAL CANCER.

Carethers J Trans Am Clin Climatol Assoc. 2024; 134:181-199.

PMID: 39135583 PMC: 11316861.


Trends in mortality from gastrointestinal, hepatic, and pancreatic cancers in the United States: A comprehensive analysis (1999-2020).

Ali H, Ishtiaq R, Tedder B, Zweigle J, Nomigolzar R, Dahiya D JGH Open. 2024; 8(4):e13064.

PMID: 38623490 PMC: 11017855. DOI: 10.1002/jgh3.13064.


Improving Noninvasive Colorectal Cancer Screening.

Carethers J N Engl J Med. 2024; 390(11):1045-1046.

PMID: 38477992 PMC: 11016370. DOI: 10.1056/NEJMe2400366.

References
1.
Venugopal A, Carethers J . Epidemiology and biology of early onset colorectal cancer. EXCLI J. 2022; 21:162-182. PMC: 8859644. DOI: 10.17179/excli2021-4456. View

2.
Corley D, Jensen C, Marks A, Zhao W, de Boer J, Levin T . Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol. 2012; 11(2):172-80. PMC: 3954741. DOI: 10.1016/j.cgh.2012.09.010. View

3.
Kelly J, Alberts S, Sacco F, Lanier A . Colorectal cancer in alaska native people, 2005-2009. Gastrointest Cancer Res. 2012; 5(5):149-54. PMC: 3481146. View

4.
Hornschuch M, Schwarz S, Haug U . 10-year prevalence of diagnostic and screening colonoscopy use in Germany: a claims data analysis. Eur J Cancer Prev. 2022; 31(6):497-504. PMC: 9928559. DOI: 10.1097/CEJ.0000000000000736. View

5.
Carethers J, Doubeni C . Causes of Socioeconomic Disparities in Colorectal Cancer and Intervention Framework and Strategies. Gastroenterology. 2019; 158(2):354-367. PMC: 6957741. DOI: 10.1053/j.gastro.2019.10.029. View